APAC Cancer Immunotherapy Market - Industry Trends and Forecast to 2032

Description

List of Tables

The Asia-Pacific cancer immunotherapy market is expected to reach USD 28,527.61 million by 2031 from USD 9,669.65 million in 2023, growing at a CAGR of 15.4% during the forecast period of 2024 to 2031.

Market Segmentation

Asia-Pacific Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, New Zealand, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2031.

Overview of Asia-Pacific Cancer Immunotherapy Market Dynamics

Driver
Rising prevalence of cancer incidences
Restraint
Increasing occurrence of immune-related adverse events
Opportunity
Growing trend towards combination therapies

Market Players

Some of the major market players operating in the Asia-Pacific cancer immunotherapy market are listed below:

Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Company
Janssen Pharmaceutical
AstraZeneca
Gilead Sciences, Inc.
Eli Lilly and Company
Amgen Inc.
Novartis AG
GSK
Pfizer Inc.
Incyte

1 INTRODUCTION 83

1.1 OBJECTIVES OF THE STUDY 83
1.2 MARKET DEFINITION 83
1.3 OVERVIEW OF THE ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET 83
1.4 CURRENCY AND PRICING 85
1.5 LIMITATIONS 85
1.6 MARKETS COVERED 85

2 MARKET SEGMENTATION 89

2.1 MARKETS COVERED 89
2.2 GEOGRAPHICAL SCOPE 90
2.3 YEARS CONSIDERED FOR THE STUDY 91
2.4 DBMR TRIPOD DATA VALIDATION MODEL 92
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 95
2.6 MULTIVARIATE MODELLING 96
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 96
2.8 MARKET END USER COVERAGE GRID 97
2.9 DBMR MARKET POSITION GRID 98
2.10 VENDOR SHARE ANALYSIS 99
2.11 SECONDARY SOURCES 100
2.12 ASSUMPTIONS 100

3 EXECUTIVE SUMMARY 101

4 PREMIUM INSIGHTS 103

4.1 PESTAL ANALYSIS 104
4.2 PORTERS 5 FORCES 105

5 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: REGULATIONS 106

6 MARKET OVERVIEW 114

6.1 DRIVERS 116
- 6.1.1 RISING PREVALENCE OF CANCER INCIDENCES 116
- 6.1.2 RISING TECHNOLOGICAL ADVANCEMENTS 116
- 6.1.3 INCREASED UNDERSTANDING OF TUMOR MICROENVIRONMENT 117
- 6.1.4 RISE IN PATIENT AWARENESS AND DEMAND FOR TARGETED TREATMENT 117
6.2 RESTRAINTS 118
- 6.2.1 INCREASING OCCURRENCE OF IMMUNE-RELATED ADVERSE EVENTS 118
- 6.2.2 DEVELOPING RESISTANCE TO CANCER TREATMENT 118
6.3 OPPORTUNITIES 119
- 6.3.1 GROWING TREND TOWARDS COMBINATION THERAPIES 119
- 6.3.2 RISING INTEGRATION OF ARTIFICIAL INTELLIGENCE AND DIGITAL HEALTH TOOLS 119
- 6.3.3 DEVELOPMENT OF NEXT-GENERATION IMMUNOTHERAPIES 120
6.4 CHALLENGES 121
- 6.4.1 LACK OF STANDARDIZATION IN BIOMARKER TESTING 121
- 6.4.2 COMPLEXITY OF DEVELOPING AND IMPLEMENTING PERSONALIZED MEDICINE 121

7 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE 122

7.1 OVERVIEW 123
7.2 CHECKPOINT INHIBITORS 126
- 7.2.1 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1) 127
- 7.2.2 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 127
7.3 MONOCLONAL ANTIBODIES 128
- 7.3.1 NAKED MONOCLONAL ANTIBODIES 129
- 7.3.2 CONJUGATED MONOCLONAL ANTIBODIES 129
- 7.3.3 BISPECIFIC MONOCLONAL ANTIBODIES 129
7.4 VACCINES 130
- 7.4.1 PROPHYLACTIC VACCINES 131
- 7.4.2 THERAPEUTIC VACCINES 131
7.5 CELL THERAPIES 131
- 7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 132
- 7.5.2 T CELL THERAPY 132
7.6 IMMUNOMODULATORS 132
- 7.6.1 INTERFERONS 133
- 7.6.2 INTERLEUKINS 133
- 7.6.3 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR 133
7.7 ONCOLYTIC VIRUS 134

8 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY END USER 135

8.1 OVERVIEW 136
8.2 HOSPITALS 139
8.3 ONCOLOGY CLINICS 140
8.4 HOMECARE 140
8.5 OTHERS 141

9 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 142

9.1 OVERVIEW 143
9.2 DIRECT TENDERS 146
9.3 RETAIL SALES 147
9.4 PHARMACIES 147
- 9.4.1 HOSPITAL 148
- 9.4.2 RETAIL 148
- 9.4.3 ONLINE 148

10 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY FORM 149

10.1 OVERVIEW 150
10.2 INTRAVENOUS (IV) 153
10.3 INTRAMUSCULAR 154
10.4 ORAL 154

11 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 155

11.1 OVERVIEW 156
11.2 LUNG CANCER 159
- 11.2.1 CHECKPOINT INHIBITORS 160
- 11.2.2 MONOCLONAL ANTIBODIES 160
- 11.2.3 CELL THERAPIES 160
- 11.2.4 IMMUNOMODULATORS 160
11.3 BREAST CANCER 161
- 11.3.1 CHECKPOINT INHIBITORS 161
- 11.3.2 MONOCLONAL ANTIBODIES 161
- 11.3.3 CELL THERAPIES 162
- 11.3.4 IMMUNOMODULATORS 162
11.4 MELANOMA 162
- 11.4.1 CHECKPOINT INHIBITORS 163
- 11.4.2 MONOCLONAL ANTIBODIES 163
- 11.4.3 CELL THERAPIES 163
- 11.4.4 IMMUNOMODULATORS 163
- 11.4.5 ONCOLYTIC VIRUS 163
11.5 MULTIPLE MYELOMA 164
- 11.5.1 CHECKPOINT INHIBITORS 164
- 11.5.2 MONOCLONAL ANTIBODIES 164
- 11.5.3 CELL THERAPIES 164
- 11.5.4 IMMUNOMODULATORS 165
11.6 PROSTATE CANCER 165
- 11.6.1 CHECKPOINT INHIBITORS 165
- 11.6.2 MONOCLONAL ANTIBODIES 166
- 11.6.3 CELL THERAPIES 166
- 11.6.4 IMMUNOMODULATORS 166
- 11.6.5 VACCINES 166
11.7 OVARIAN CANCER 166
- 11.7.1 CHECKPOINT INHIBITORS 167
- 11.7.2 MONOCLONAL ANTIBODIES 167
- 11.7.3 CELL THERAPIES 167
- 11.7.4 IMMUNOMODULATORS 167
11.8 CERVICAL CANCER 168
- 11.8.1 CHECKPOINT INHIBITORS 168
- 11.8.2 MONOCLONAL ANTIBODIES 168
- 11.8.3 VACCINES 169
- 11.8.4 CELL THERAPIES 169
- 11.8.5 IMMUNOMODULATORS 169
11.9 STOMACH CANCER 169
- 11.9.1 CHECKPOINT INHIBITORS 170
- 11.9.2 MONOCLONAL ANTIBODIES 170
- 11.9.3 CELL THERAPIES 170
- 11.9.4 IMMUNOMODULATORS 170
11.10 COLORECTAL CANCER 170
- 11.10.1 CHECKPOINT INHIBITORS 171
- 11.10.2 MONOCLONAL ANTIBODIES 171
- 11.10.3 CELL THERAPIES 171
- 11.10.4 IMMUNOMODULATORS 171
11.11 HEAD AND NECK CANCER 172
- 11.11.1 CHECKPOINT INHIBITORS 172
- 11.11.2 MONOCLONAL ANTIBODIES 172
- 11.11.3 CELL THERAPIES 172
- 11.11.4 IMMUNOMODULATORS 173
11.12 OTHERS 173
- 11.12.1 CHECKPOINT INHIBITORS 173
- 11.12.2 MONOCLONAL ANTIBODIES 173
- 11.12.3 VACCINES 174
- 11.12.4 CELL THERAPIES 174
- 11.12.5 IMMUNOMODULATORS 174

12 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY REGION 175

12.1 ASIA-PACIFIC 177
- 12.1.1 CHINA 186
- 12.1.2 JAPAN 194
- 12.1.3 INDIA 202
- 12.1.4 SOUTH KOREA 210
- 12.1.5 AUSTRALIA 218
- 12.1.6 SINGAPORE 227
- 12.1.7 THAILAND 236
- 12.1.8 INDONESIA 244
- 12.1.9 PHILIPPINES 253
- 12.1.10 MALAYSIA 262
- 12.1.11 VIETNAM 270
- 12.1.12 REST OF ASIA-PACIFIC 278

13 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, COMPANY LANDSCAPE 279

13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 279

14 SWOT ANALYSIS 280

15 COMPANY PROFILES 281

15.1 MERCK & CO., INC. 281
- 15.1.1 COMPANY SNAPSHOT 281
- 15.1.2 REVENUE ANALYSIS 281
- 15.1.3 COMPANY SHARE ANALYSIS 282
- 15.1.4 PRODUCT PORTFOLIO 282
- 15.1.5 RECENT DEVELOPMENTS 282
15.2 F. HOFFMANN-LA ROCHE LTD 283
- 15.2.1 COMPANY SNAPSHOT 283
- 15.2.2 REVENUE ANALYSIS 283
- 15.2.3 COMPANY SHARE ANALYSIS 284
- 15.2.4 PRODUCT PORTFOLIO 284
- 15.2.5 RECENT DEVELOPMENTS 284
15.3 BRISTOL-MYERS SQUIBB COMPANY 286
- 15.3.1 COMPANY SNAPSHOT 286
- 15.3.2 REVENUE ANALYSIS 286
- 15.3.3 COMPANY SHARE ANALYSIS 287
- 15.3.4 PRODUCT PORTFOLIO 287
- 15.3.5 RECENT DEVELOPMENTS 288
15.4 JANSSEN ASIA PACIFIC SERVICES, LLC 289
- 15.4.1 COMPANY SNAPSHOT 289
- 15.4.2 REVENUE ANALYSIS 289
- 15.4.3 COMPANY SHARE ANALYSIS 290
- 15.4.4 PRODUCT PORTFOLIO 290
- 15.4.5 RECENT DEVELOPMENTS 291
15.5 ASTRAZENECA 292
- 15.5.1 COMPANY SNAPSHOT 292
- 15.5.2 REVENUE ANALYSIS 292
- 15.5.3 COMPANY SHARE ANALYSIS 293
- 15.5.4 PRODUCT PORTFOLIO 293
- 15.5.5 RECENT DEVELOPMENTS 294
15.6 ABBVIE INC. 295
- 15.6.1 COMPANY SNAPSHOT 295
- 15.6.2 PIPELINE PORTFOLIO 295
- 15.6.3 RECENT DEVELOPMENTS 295
15.7 AMGEN INC. 296
- 15.7.1 COMPANY SNAPSHOT 296
- 15.7.2 REVENUE ANALYSIS 297
- 15.7.3 PIPELINE PORTFOLIO 297
- 15.7.4 PRODUCT PORTFOLIO 298
- 15.7.5 RECENT DEVELOPMENTS 298
15.8 ATARA BIOTHERAPEUTICS, INC. 299
- 15.8.1 COMPANY SNAPSHOT 299
- 15.8.2 PIPELINE PORTFOLIO 299
- 15.8.3 RECENT DEVELOPMENTS 299
15.9 BAYER AG 300
- 15.9.1 COMPANY SNAPSHOT 300
- 15.9.2 PIPELINE PORTFOLIO 300
- 15.9.3 RECENT DEVELOPMENTS 300
15.10 CELLDEX THERAPEUTICS. 302
- 15.10.1 COMPANY SNAPSHOT 302
- 15.10.2 PIPELINE PORTFOLIO 302
- 15.10.3 RECENT DEVELOPMENTS 302
15.11 CELLECTIS 303
- 15.11.1 COMPANY SNAPSHOT 303
- 15.11.2 PIPELINE PORTFOLIO 303
- 15.11.3 RECENT DEVELOPMENTS 303
15.12 GILEAD SCIENCES, INC. 304
- 15.12.1 COMPANY SNAPSHOT 304
- 15.12.2 REVENUE ANALYSIS 304
- 15.12.3 PRODUCT PORTFOLIO 305
- 15.12.4 RECENT DEVELOPMENTS 305
15.13 GSK PLC. 306
- 15.13.1 COMPANY SNAPSHOT 306
- 15.13.2 REVENUE ANALYSIS 306
- 15.13.3 PRODUCT PORTFOLIO 307
- 15.13.4 RECENT DEVELOPMENTS 307
15.14 INCYTE. 308
- 15.14.1 COMPANY SNAPSHOT 308
- 15.14.2 REVENUE ANALYSIS 308
- 15.14.3 PRODUCT PORTFOLIO 309
- 15.14.4 RECENT DEVELOPMENTS 309
15.15 LILLY. 310
- 15.15.1 COMPANY SNAPSHOT 310
- 15.15.2 REVENUE ANALYSIS 311
- 15.15.3 PRODUCT PORTFOLIO 311
- 15.15.4 RECENT DEVELOPMENTS 312
15.16 NOVARTIS AG 313
- 15.16.1 COMPANY SNAPSHOT 313
- 15.16.2 REVENUE ANALYSIS 313
- 15.16.3 PIPELINE PORTFOLIO 314
- 15.16.4 PRODUCT PORTFOLIO 314
- 15.16.5 RECENT DEVELOPMENTS 314
15.17 PFIZER INC. 315
- 15.17.1 COMPANY SNAPSHOT 315
- 15.17.2 REVENUE ANALYSIS 315
- 15.17.3 PRODUCT PORTFOLIO 316
- 15.17.4 RECENT DEVELOPMENTS 316

16 QUESTIONNAIRE 317

17 RELATED REPORTS 321

LIST OF TABLES

TABLE 1 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY PRODUCT TYPE, 2022- 2031 (USD MILLION) 76
TABLE 2 ASIA PACIFIC CHECKPOINT INHIBITORS CANCER IMMUNOTHERAPY IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 76
TABLE 3 ASIA PACIFIC CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 77
TABLE 4 ASIA PACIFIC CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (UNITS) 77
TABLE 5 ASIA PACIFIC MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 78
TABLE 6 ASIA PACIFIC MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 78
TABLE 7 ASIA PACIFIC MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (UNITS) 79
TABLE 8 ASIA PACIFIC VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 80
TABLE 9 ASIA PACIFIC VACCINES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 80
TABLE 10 ASIA PACIFIC VACCINES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (UNITS) 80
TABLE 11 ASIA PACIFIC CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 81
TABLE 12 ASIA PACIFIC CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 81
TABLE 13 ASIA PACIFIC CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (UNITS) 82
TABLE 14 ASIA PACIFIC IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 82
TABLE 15 ASIA PACIFIC IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET , BY TYPE, 2022- 2031 (USD MILLION) 83
TABLE 16 ASIA PACIFIC IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 83
TABLE 17 ASIA PACIFIC ONCOLYTIC VIRUS IN CANCER IMMUNOTHERAPYMARKET, BY REGION, 2022-2031 (USD MILLION) 84
TABLE 18 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET , BY END USER, 2022- 2031 (USD MILLION) 89
TABLE 19 ASIA PACIFIC HOSPITALS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 89
TABLE 20 ASIA PACIFIC ONCOLOGY CLINICS IN CANCER IMMUNOTHERAPY IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 90
TABLE 21 ASIA PACIFIC HOMECARE IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 90
TABLE 22 ASIA PACIFIC OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 91
TABLE 23 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 96
TABLE 24 ASIA PACIFIC DIRECT TENDERS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 96
TABLE 25 ASIA PACIFIC RETAIL SALES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 97
TABLE 26 ASIA PACIFIC PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 97
TABLE 27 ASIA PACIFIC PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 98
TABLE 28 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 103
TABLE 29 ASIA PACIFIC INTRAVENOUS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 103
TABLE 30 ASIA PACIFIC INTRAMUSCULAR IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 104
TABLE 31 ASIA PACIFIC ORAL IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 104
TABLE 32 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 109
TABLE 33 ASIA PACIFIC LUNG CANCERI N CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 109
TABLE 34 ASIA PACIFIC LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 110
TABLE 35 ASIA PACIFIC BREAST CANCERI N CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 111
TABLE 36 ASIA PACIFIC BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 111
TABLE 37 ASIA PACIFIC MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 112
TABLE 38 ASIA PACIFIC MELANOMA CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 112
TABLE 39 ASIA PACIFIC MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 114
TABLE 40 ASIA PACIFIC MULTIPLE MYELOMA CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 114
TABLE 41 ASIA PACIFIC PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 115
TABLE 42 ASIA PACIFIC PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 115
TABLE 43 ASIA PACIFIC OVARIANC ANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 116
TABLE 44 ASIA PACIFIC OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 117
TABLE 45 ASIA PACIFIC CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 118
TABLE 46 ASIA PACIFIC CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 118
TABLE 47 ASIA PACIFIC STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 119
TABLE 48 ASIA PACIFIC STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 119
TABLE 49 ASIA PACIFIC COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 120
TABLE 50 ASIA PACIFIC COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 121
TABLE 51 ASIA PACIFIC HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 122
TABLE 52 ASIA PACIFIC HEAD & NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 122
TABLE 53 ASIA PACIFIC OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY REGION, 2022-2031 (USD MILLION) 123
TABLE 54 ASIA PACIFIC OTHERS CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 123
TABLE 55 ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 127
TABLE 56 ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 127
TABLE 57 ASIA-PACIFIC CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 128
TABLE 58 ASIA-PACIFIC CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 128
TABLE 59 ASIA-PACIFIC MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 128
TABLE 60 ASIA-PACIFIC MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 129
TABLE 61 ASIA-PACIFIC VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 129
TABLE 62 ASIA-PACIFIC VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 129
TABLE 63 ASIA-PACIFIC CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 129
TABLE 64 ASIA-PACIFIC CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 130
TABLE 65 ASIA-PACIFIC IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 130
TABLE 66 ASIA-PACIFIC IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 130
TABLE 67 ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 131
TABLE 68 ASIA-PACIFIC LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
TABLE 69 ASIA-PACIFIC BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 131
TABLE 70 ASIA-PACIFIC MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
TABLE 71 ASIA-PACIFIC MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
TABLE 72 ASIA-PACIFIC PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
TABLE 73 ASIA-PACIFIC OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 132
TABLE 74 ASIA-PACIFIC CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 133
TABLE 75 ASIA-PACIFIC STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 133
TABLE 76 ASIA-PACIFIC COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 133
TABLE 77 ASIA-PACIFIC HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 134
TABLE 78 ASIA-PACIFIC OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 134
TABLE 79 ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 134
TABLE 80 ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 134
TABLE 81 ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 135
TABLE 82 ASIA-PACIFIC PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 135
TABLE 83 CHINA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 136
TABLE 84 CHINA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 136
TABLE 85 CHINA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 136
TABLE 86 CHINA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 136
TABLE 87 CHINA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 137
TABLE 88 CHINA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 137
TABLE 89 CHINA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 137
TABLE 90 CHINA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 137
TABLE 91 CHINA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 138
TABLE 92 CHINA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 138
TABLE 93 CHINA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 138
TABLE 94 CHINA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 138
TABLE 95 CHINA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 138
TABLE 96 CHINA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 139
TABLE 97 CHINA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 139
TABLE 98 CHINA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 139
TABLE 99 CHINA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 139
TABLE 100 CHINA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 140
TABLE 101 CHINA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 140
TABLE 102 CHINA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 140
TABLE 103 CHINA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 140
TABLE 104 CHINA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
TABLE 105 CHINA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
TABLE 106 CHINA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
TABLE 107 CHINA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 141
TABLE 108 CHINA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
TABLE 109 CHINA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
TABLE 110 CHINA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 142
TABLE 111 CHINA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 142
TABLE 112 CHINA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 143
TABLE 113 CHINA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 143
TABLE 114 CHINA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 143
TABLE 115 JAPAN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 144
TABLE 116 JAPAN CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 144
TABLE 117 JAPAN CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 144
TABLE 118 JAPAN CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 144
TABLE 119 JAPAN MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 145
TABLE 120 JAPAN MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 145
TABLE 121 JAPAN MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 145
TABLE 122 JAPAN VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 145
TABLE 123 JAPAN VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 145
TABLE 124 JAPAN VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 146
TABLE 125 JAPAN CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 146
TABLE 126 JAPAN CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 146
TABLE 127 JAPAN CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 146
TABLE 128 JAPAN IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 146
TABLE 129 JAPAN IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 147
TABLE 130 JAPAN IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 147
TABLE 131 JAPAN CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 147
TABLE 132 JAPAN LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 147
TABLE 133 JAPAN BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 148
TABLE 134 JAPAN MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 148
TABLE 135 JAPAN MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 148
TABLE 136 JAPAN PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 148
TABLE 137 JAPAN OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 149
TABLE 138 JAPAN CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 149
TABLE 139 JAPAN STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 149
TABLE 140 JAPAN COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 149
TABLE 141 JAPAN HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 150
TABLE 142 JAPAN OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 150
TABLE 143 JAPAN CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 150
TABLE 144 JAPAN CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 150
TABLE 145 JAPAN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 151
TABLE 146 JAPAN PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 151
TABLE 147 INDIA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 152
TABLE 148 INDIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 152
TABLE 149 INDIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 152
TABLE 150 INDIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 152
TABLE 151 INDIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 153
TABLE 152 INDIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 153
TABLE 153 INDIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 153
TABLE 154 INDIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 153
TABLE 155 INDIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 153
TABLE 156 INDIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 154
TABLE 157 INDIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 154
TABLE 158 INDIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 154
TABLE 159 INDIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 154
TABLE 160 INDIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 154
TABLE 161 INDIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 155
TABLE 162 INDIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 155
TABLE 163 INDIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 155
TABLE 164 INDIA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 155
TABLE 165 INDIA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 156
TABLE 166 INDIA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 156
TABLE 167 INDIA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 156
TABLE 168 INDIA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 156
TABLE 169 INDIA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
TABLE 170 INDIA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
TABLE 171 INDIA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
TABLE 172 INDIA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 157
TABLE 173 INDIA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 158
TABLE 174 INDIA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 158
TABLE 175 INDIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 158
TABLE 176 INDIA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 158
TABLE 177 INDIA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 159
TABLE 178 INDIA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 159
TABLE 179 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 160
TABLE 180 SOUTH KOREA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 160
TABLE 181 SOUTH KOREA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 160
TABLE 182 SOUTH KOREA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 160
TABLE 183 SOUTH KOREA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 161
TABLE 184 SOUTH KOREA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 161
TABLE 185 SOUTH KOREA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 161
TABLE 186 SOUTH KOREA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 161
TABLE 187 SOUTH KOREA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 162
TABLE 188 SOUTH KOREA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 162
TABLE 189 SOUTH KOREA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 162
TABLE 190 SOUTH KOREA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 162
TABLE 191 SOUTH KOREA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 162
TABLE 192 SOUTH KOREA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 163
TABLE 193 SOUTH KOREA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 163
TABLE 194 SOUTH KOREA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 163
TABLE 195 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 163
TABLE 196 SOUTH KOREA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 164
TABLE 197 SOUTH KOREA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 164
TABLE 198 SOUTH KOREA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 164
TABLE 199 SOUTH KOREA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 164
TABLE 200 SOUTH KOREA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 165
TABLE 201 SOUTH KOREA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 165
TABLE 202 SOUTH KOREA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 165
TABLE 203 SOUTH KOREA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
TABLE 204 SOUTH KOREA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
TABLE 205 SOUTH KOREA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
TABLE 206 SOUTH KOREA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 166
TABLE 207 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 167
TABLE 208 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 167
TABLE 209 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 167
TABLE 210 SOUTH KOREA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 167
TABLE 211 AUSTRALIA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 168
TABLE 212 AUSTRALIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 168
TABLE 213 AUSTRALIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 168
TABLE 214 AUSTRALIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 169
TABLE 215 AUSTRALIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 169
TABLE 216 AUSTRALIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 169
TABLE 217 AUSTRALIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 169
TABLE 218 AUSTRALIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 170
TABLE 219 AUSTRALIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 170

TABLE 220 AUSTRALIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 170
TABLE 221 AUSTRALIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 170
TABLE 222 AUSTRALIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 170
TABLE 223 AUSTRALIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 171
TABLE 224 AUSTRALIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 171
TABLE 225 AUSTRALIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 171
TABLE 226 AUSTRALIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 171
TABLE 227 AUSTRALIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 172
TABLE 228 AUSTRALIA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
TABLE 229 AUSTRALIA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 172
TABLE 230 AUSTRALIA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 173
TABLE 231 AUSTRALIA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 173
TABLE 232 AUSTRALIA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 173
TABLE 233 AUSTRALIA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 173
TABLE 234 AUSTRALIA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 174
TABLE 235 AUSTRALIA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 174
TABLE 236 AUSTRALIA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 174
TABLE 237 AUSTRALIA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 174
TABLE 238 AUSTRALIA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 175
TABLE 239 AUSTRALIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 175
TABLE 240 AUSTRALIA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 175
TABLE 241 AUSTRALIA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 175
TABLE 242 AUSTRALIA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 176
TABLE 243 SINGAPORE CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 177
TABLE 244 SINGAPORE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 177
TABLE 245 SINGAPORE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 177
TABLE 246 SINGAPORE CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 178
TABLE 247 SINGAPORE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 178
TABLE 248 SINGAPORE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 178
TABLE 249 SINGAPORE MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 178
TABLE 250 SINGAPORE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 179
TABLE 251 SINGAPORE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 179
TABLE 252 SINGAPORE VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 179
TABLE 253 SINGAPORE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 179
TABLE 254 SINGAPORE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 179
TABLE 255 SINGAPORE CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 180
TABLE 256 SINGAPORE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 180
TABLE 257 SINGAPORE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 180
TABLE 258 SINGAPORE IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 180
TABLE 259 SINGAPORE CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 181
TABLE 260 SINGAPORE LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 181
TABLE 261 SINGAPORE BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 181
TABLE 262 SINGAPORE MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 182
TABLE 263 SINGAPORE MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 182
TABLE 264 SINGAPORE PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 182
TABLE 265 SINGAPORE OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 182
TABLE 266 SINGAPORE CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 183
TABLE 267 SINGAPORE STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 183
TABLE 268 SINGAPORE COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 183
TABLE 269 SINGAPORE HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 183
TABLE 270 SINGAPORE OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 184
TABLE 271 SINGAPORE CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 184
TABLE 272 SINGAPORE CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 184
TABLE 273 SINGAPORE CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 184
TABLE 274 SINGAPORE PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 185
TABLE 275 THAILAND CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 186
TABLE 276 THAILAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 186
TABLE 277 THAILAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 186
TABLE 278 THAILAND CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 186
TABLE 279 THAILAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 187
TABLE 280 THAILAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 187
TABLE 281 THAILAND MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 187
TABLE 282 THAILAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 187
TABLE 283 THAILAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 187
TABLE 284 THAILAND VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 188
TABLE 285 THAILAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 188
TABLE 286 THAILAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 188
TABLE 287 THAILAND CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 188
TABLE 288 THAILAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 188
TABLE 289 THAILAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 189
TABLE 290 THAILAND IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 189
TABLE 291 THAILAND CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 189
TABLE 292 THAILAND LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 189
TABLE 293 THAILAND BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 190
TABLE 294 THAILAND MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 190
TABLE 295 THAILAND MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 190
TABLE 296 THAILAND PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 190
TABLE 297 THAILAND OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 191
TABLE 298 THAILAND CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 191
TABLE 299 THAILAND STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 191
TABLE 300 THAILAND COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 191
TABLE 301 THAILAND HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 192
TABLE 302 THAILAND OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 192
TABLE 303 THAILAND CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 192
TABLE 304 THAILAND CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 192
TABLE 305 THAILAND CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 193
TABLE 306 THAILAND PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 193
TABLE 307 INDONESIA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 194
TABLE 308 INDONESIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 194
TABLE 309 INDONESIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 194
TABLE 310 INDONESIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 195
TABLE 311 INDONESIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 195
TABLE 312 INDONESIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 195
TABLE 313 INDONESIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 195
TABLE 314 INDONESIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 196
TABLE 315 INDONESIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 196
TABLE 316 INDONESIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 196
TABLE 317 INDONESIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 196
TABLE 318 INDONESIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 196
TABLE 319 INDONESIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 197
TABLE 320 INDONESIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 197
TABLE 321 INDONESIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 197
TABLE 322 INDONESIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 197
TABLE 323 INDONESIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 198
TABLE 324 INDONESIA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 198
TABLE 325 INDONESIA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 198
TABLE 326 INDONESIA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 199
TABLE 327 INDONESIA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 199
TABLE 328 INDONESIA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 199
TABLE 329 INDONESIA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 199
TABLE 330 INDONESIA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 200
TABLE 331 INDONESIA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 200
TABLE 332 INDONESIA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 200
TABLE 333 INDONESIA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 200
TABLE 334 INDONESIA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 201
TABLE 335 INDONESIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 201
TABLE 336 INDONESIA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 201
TABLE 337 INDONESIA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 201
TABLE 338 INDONESIA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 202
TABLE 339 PHILIPPINES CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 203
TABLE 340 PHILIPPINES CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 203
TABLE 341 PHILIPPINES CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 203
TABLE 342 PHILIPPINES CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 204
TABLE 343 PHILIPPINES MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 204
TABLE 344 PHILIPPINES MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 204
TABLE 345 PHILIPPINES MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 204
TABLE 346 PHILIPPINES VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 205
TABLE 347 PHILIPPINES VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 205
TABLE 348 PHILIPPINES VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 205
TABLE 349 PHILIPPINES CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 205
TABLE 350 PHILIPPINES CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 205
TABLE 351 PHILIPPINES CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 206
TABLE 352 PHILIPPINES IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 206
TABLE 353 PHILIPPINES IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 206
TABLE 354 PHILIPPINES IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 206
TABLE 355 PHILIPPINES CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 207
TABLE 356 PHILIPPINES LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 207
TABLE 357 PHILIPPINES BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 207
TABLE 358 PHILIPPINES MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 208
TABLE 359 PHILIPPINES MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 208
TABLE 360 PHILIPPINES PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 208
TABLE 361 PHILIPPINES OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 208
TABLE 362 PHILIPPINES CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 209
TABLE 363 PHILIPPINES STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 209
TABLE 364 PHILIPPINES COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 209
TABLE 365 PHILIPPINES HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 209
TABLE 366 PHILIPPINES OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 210
TABLE 367 PHILIPPINES CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 210
TABLE 368 PHILIPPINES CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 210
TABLE 369 PHILIPPINES CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 210
TABLE 370 PHILIPPINES PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 211
TABLE 371 MALAYSIA CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 212
TABLE 372 MALAYSIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 212
TABLE 373 MALAYSIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 212
TABLE 374 MALAYSIA CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 212
TABLE 375 MALAYSIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 213
TABLE 376 MALAYSIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 213
TABLE 377 MALAYSIA MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 213
TABLE 378 MALAYSIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 213
TABLE 379 MALAYSIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 213
TABLE 380 MALAYSIA VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 214
TABLE 381 MALAYSIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 214
TABLE 382 MALAYSIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 214
TABLE 383 MALAYSIA CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 214
TABLE 384 MALAYSIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 214
TABLE 385 MALAYSIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 215
TABLE 386 MALAYSIA IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 215
TABLE 387 MALAYSIA CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 215
TABLE 388 MALAYSIA LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 215
TABLE 389 MALAYSIA BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 216
TABLE 390 MALAYSIA MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 216
TABLE 391 MALAYSIA MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 216
TABLE 392 MALAYSIA PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 216
TABLE 393 MALAYSIA OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 217
TABLE 394 MALAYSIA CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 217
TABLE 395 MALAYSIA STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 217
TABLE 396 MALAYSIA COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 217
TABLE 397 MALAYSIA HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
TABLE 398 MALAYSIA OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 218
TABLE 399 MALAYSIA CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 218
TABLE 400 MALAYSIA CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 218
TABLE 401 MALAYSIA CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 219
TABLE 402 MALAYSIA PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 219
TABLE 403 VIETNAM CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 220
TABLE 404 VIETNAM CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 220
TABLE 405 VIETNAM CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 220
TABLE 406 VIETNAM CHECKPOINT INHIBITORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 220
TABLE 407 VIETNAM MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 221
TABLE 408 VIETNAM MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 221
TABLE 409 VIETNAM MONOCLONAL ANTIBODIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 221
TABLE 410 VIETNAM VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 221
TABLE 411 VIETNAM VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 221
TABLE 412 VIETNAM VACCINES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 222
TABLE 413 VIETNAM CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 222
TABLE 414 VIETNAM CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 222
TABLE 415 VIETNAM CELL THERAPIES IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 222
TABLE 416 VIETNAM IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION) 222
TABLE 417 VIETNAM IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031 (UNITS) 223
TABLE 418 VIETNAM IMMUNOMODULATORS IN CANCER IMMUNOTHERAPY MARKET, BY TYPE, 2022-2031, (ASP) 223
TABLE 419 VIETNAM CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2022-2031 (USD MILLION) 223
TABLE 420 VIETNAM LUNG CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 223
TABLE 421 VIETNAM BREAST CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 224
TABLE 422 VIETNAM MELANOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 224
TABLE 423 VIETNAM MULTIPLE MYELOMA IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 224
TABLE 424 VIETNAM PROSTATE CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 225
TABLE 425 VIETNAM OVARIAN CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 225
TABLE 426 VIETNAM CERVICAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 225
TABLE 427 VIETNAM STOMACH CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 225
TABLE 428 VIETNAM COLORECTAL CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
TABLE 429 VIETNAM HEAD AND NECK CANCER IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
TABLE 430 VIETNAM OTHERS IN CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 226
TABLE 431 VIETNAM CANCER IMMUNOTHERAPY MARKET, BY END USER, 2022-2031 (USD MILLION) 226
TABLE 432 VIETNAM CANCER IMMUNOTHERAPY MARKET, BY FORM, 2022-2031 (USD MILLION) 227
TABLE 433 VIETNAM CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 227
TABLE 434 VIETNAM PHARMACIES IN CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 227
TABLE 435 REST OF ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 228

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: SEGMENTATION 39
FIGURE 2 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: DATA TRIANGULATION 42
FIGURE 3 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: DROC ANALYSIS 43
FIGURE 4 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 44
FIGURE 5 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: COMPANY RESEARCH ANALYSIS 44
FIGURE 6 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: INTERVIEW DEMOGRAPHICS 45
FIGURE 7 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: MARKET END USER COVERAGE GRID 47
FIGURE 8 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: DBMR MARKET POSITION GRID 48
FIGURE 9 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: VENDOR SHARE ANALYSIS 49
FIGURE 10 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: SEGMENTATION 52
FIGURE 11 RISING PREVALENCE OF CANCER AND RISING TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET FROM 2024 TO 2034 53
FIGURE 12 CHECKPOINT INHIBITORS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC CANCER CHEMOTHERAPY CONSUMABLES MARKET IN 2024 TO 2031 53
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET 65
FIGURE 14 ASIA PACIFIC CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, 2023 73
FIGURE 15 ASIA PACIFIC CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, 2024-2031 (USD MILLION) 74
FIGURE 16 ASIA PACIFIC CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, CAGR (2024-2031) 74
FIGURE 17 ASIA PACIFIC CANCER IMMUNOTHERAPYMARKET : BY PRODUCT TYPE, LIFELINE CURVE 75
FIGURE 18 ASIA PACIFIC CANCER IMMUNOTHERAPYMARKET : BY END USER, 2023 86
FIGURE 19 ASIA PACIFIC CANCER IMMUNOTHERAPYMARKET : BY END USER, 2024-2031 (USD MILLION) 87
FIGURE 20 ASIA PACIFIC CANCER IMMUNOTHERAPYMARKET : BY END USER, CAGR (2024-2031) 87
FIGURE 21 ASIA PACIFIC CANCER IMMUNOTHERAPYMARKET : BY END USER, LIFELINE CURVE 88
FIGURE 22 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, 2023 93
FIGURE 23 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 94
FIGURE 24 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 94
FIGURE 25 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 95
FIGURE 26 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY FORM, 2023 100
FIGURE 27 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY FORM, 2024-2031 (USD MILLION) 101
FIGURE 28 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY FORM, CAGR (2024-2031) 101
FIGURE 29 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY FORM, LIFELINE CURVE 102
FIGURE 30 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, 2023 106
FIGURE 31 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, 2024-2031 (USD MILLION) 107
FIGURE 32 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, CAGR (2024-2031) 107
FIGURE 33 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: BY APPLICATION, LIFELINE CURVE 108
FIGURE 34 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: SNAPSHOT (2023) 126
FIGURE 35 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET: COMPANY SHARE 2023 (%) 229